N-(4-Biphenylmethyl)imidazoles as Potential Therapeutics for the Treatment of Prostate Cancer: Metabolic Robustness Due to Fluorine Substitution?
作者:Frédéric Leroux、Tilman U. Hutschenreuter、Céline Charrière、Rosario Scopelliti、Rolf W. Hartmann
DOI:10.1002/hlca.200390217
日期:2003.7
is a novel therapeutic approach for treatment of prostate cancer. To increase the so-far insufficient in vivo lifetime of such compounds, the metabolically sensitive positions were blocked by F-substitution. The meta- and ortho-F-substituted compounds were prepared by selective metallation or halogen/metal permutation reactions performed on symmetrically substituted 1,1′-biphenyls. Compared with the
合成了3,3',5,5'-和2,2',6,6'-四氟取代的1-[((1,1'-联苯] -4-基)甲基] -1 H-咪唑17抑制剂α羟化酶-C17,20裂解酶(P450 17,CYP 17)。P450 17是雄激素生物合成的关键酶。它的抑制是治疗前列腺癌的一种新颖的治疗方法。为了增加这类化合物的体内寿命,目前为止,代谢敏感性位置被F-取代所阻断。的元-和邻-F取代的化合物通过选择性金属化或卤素制备/金属置换反应进行上对称取代的1,1'-联苯。与无卤化合物相比,邻位-F-取代的衍生物与活性不匹配,而间-F-取代的异构体等于或超过后者。